The incidence of renal cell carcinoma has been increasing steadily, with more than 54 000 new cases estimated to have occurred in the United States in 2008 (1).
肾细胞癌的发病率一直在稳步上升，2008年美国有超过54000新发病例
Many of these tumors are small and are detected incidentally at cross-sectional imaging (2).
许多肿瘤体积小，在横断面影像检查中偶然发现（2）。
Traditionally, the treatment for solid renal neoplasms has been complete or partial nephrectomy.
传统上，肾实质肿瘤的治疗一直以来是肾脏的完全或部分切除。
However, percutaneous image-guided tumor ablation is being used with increasing frequency as a minimally invasive treatment option in well-selected patients with renal cell carcinoma (3–7).
然而，作为有选择的肾癌患者微创治疗抉择，经皮影像引导下的肿瘤消融使用的频率正在越来越高（3–7）。
Postablation cross-sectional imaging surveillance with computed tomography (CT) and magnetic resonance (MR) imaging is essential when trying to assess treatment success and detect residual, recurrent, or metachronous tumors.
应用CT和磁共振成像对消融后部位进行监测是必不可少的，特别是当试图评估治疗成功，发现残余肿瘤以及复发或异时肿瘤的时候
操作后的影像也被作为评估治疗相关并发症和指导进一步治疗
Postprocedural imaging is also performed to evaluate for complications related to treatment and to guide further management. 术后影像学进行评估与治疗相关的并发症，并指导进一步的管理。 The appearance of renal neoplasms treated with radiofrequency ablation (RFA) has been described previously (7–10). 先前曾描述过射频消融（RFA）治疗肾肿瘤的情况（7 - 10）。
Briefly, renal tumors treated successfully with RFA tend to decrease in size over time and demonstrate lack of treatment site enhancement at follow-up imaging.
简单地说，RFA治疗成功的肾脏肿瘤往往随时间缩小，并后续显像治疗部位的缺乏增强。
In our experience, renal cell carcinomas treated with percutaneous RFA frequently develop a characteristic appearance at the ablation site at follow-up CT and MR imaging; we term this the renal halo sign.
经验中，经皮射频消融治疗的肾细胞癌在后续的CT和磁共振成像中，常常在消融部位形成特征性的表现，被称之为肾晕轮征（halo sign）。
This postablation appearance has been described previously as a “band or halo” (7), a “fibrotic halo of fat” (8), and a “bull's eye” (9) surrounding treated renal tumors.
肾肿瘤射频消融术后周边这种表现，以前也被描述为“带或晕”（7），“脂肪的纤维化晕”（8），和“牛样眼”（9）。
Ablated tumors typically become surrounded by macroscopic fat with an attenuation of less than 10 HU on CT images or with signal drop out on MR images acquired with fat suppression.
消融后的肿瘤通常被宏观脂肪所包围，CT图像上的衰减小于10，脂肪抑制获得的MR图像信号下降。
This fat may be of variable thickness, and it is surrounded by a thin (thinner than 2 mm) smooth curvilinear rim of soft-tissue attenuation at CT or a signal that is iso- or hyperintense to that of the renal parenchyma at MR imaging follow-up.
这种脂肪可能会变厚，它是被一薄层（厚度小于2毫米）在CT或信号，等或高信号，肾实质MR成像软组织衰减曲线的平滑边缘跟踪。
Radiologists not familiar with this appearance could mistake the renal halo sign for either a residual tumor or another fat-containing entity, such as an angiomyolipoma.
不熟悉这种情况的放射科医师可能会误认为肾晕征是残留肿瘤或其他含脂肪的实体，如血管平滑肌脂肪瘤。
The purpose of this article is to describe the frequency with which the renal halo sign occurs, how long after percutaneous RFA the sign will appear, and the duration that the sign will persist.
这篇文章的目的是描述肾晕轮征发生的频率，经皮射频消融术后多长时间，标志会出现，以及标志持续的时间。 |